Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.07%
1,101.37
-0.81
-0.07%
—1,102.181,096.241,103.051,090.35——
SIXC
Communications
SIXC
Communications
SIXC
-0.47%
613.35
-2.89
-0.47%
—616.24616.24617.68609.10——
SIXE
Energy
SIXE
Energy
SIXE
+0.77%
1,198.83
+9.11
+0.77%
—1,189.721,194.741,202.791,188.58——
SIXI
Industrials
SIXI
Industrials
SIXI
+1.75%
1,755.95
+30.26
+1.75%
—1,725.691,730.021,762.991,730.02——
SIXM
Financials
SIXM
Financials
SIXM
-0.79%
638.51
-5.11
-0.79%
—643.62643.13643.17632.59——
SIXR
Staples
SIXR
Staples
SIXR
+1.65%
843.52
+13.73
+1.65%
—829.79832.32845.25832.32——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+1.19%
215.95
+2.55
+1.19%
—213.40213.40216.07213.40——
SIXT
Technology
SIXT
Technology
SIXT
-1.48%
3,138.91
-47.01
-1.48%
—3,185.923,160.893,178.723,102.60——
SIXU
Utilities
SIXU
Utilities
SIXU
+2.80%
934.37
+25.43
+2.80%
—908.94912.57934.91912.57——
SIXV
Health care
SIXV
Health care
SIXV
-0.10%
1,477.43
-1.53
-0.10%
—1,478.961,478.171,482.911,466.65——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-1.05%
2,380.19
-25.17
-1.05%
—2,405.362,390.342,402.532,359.18——
NTLA:NASDAQ
Intellia Therapeutics Inc
$15.87
-4.22%
(-0.70) 1D
$16.09
+1.39% (+0.22)
Pre-market
Closed: Apr 23, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NTLA...
Open
$16.80
High
$16.97
Low
$15.56
Mkt. cap
1.87B
Avg. vol.
3.15M
Volume
2.92K
52-wk high
$28.25
52-wk low
$6.83
EPS
-$3.81
Beta
1.99
Shares outstanding
118.13M
No. of employees
377
News stories
From sources across the web
Profile
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics. Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
About Intellia Therapeutics Inc
CEOJohn Leonard
Employees377
Founded2014
HeadquartersCambridge, Massachusetts, United States
SectorBiotechnology
Websiteintelliatx.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
16.63M
14.24M
13.78M
23.02M
Cost of goods sold
108.43M
80.53M
78.95M
73.63M
Cost of revenue
108.43M
80.53M
78.95M
73.63M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
29.01M
43.71M
46.31M
48.10M
Operating expense
29.01M
43.71M
46.31M
48.10M
Total operating expenses
137.43M
124.24M
125.26M
121.73M
Operating income
-120.81M
-110.00M
-111.48M
-98.71M
Other non operating income
-
-
-
-
EBT including unusual items
-114.33M
-101.26M
-101.32M
-95.79M
EBT excluding unusual items
-112.20M
-102.59M
-104.76M
-92.23M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-114.33M
-101.26M
-101.32M
-95.79M
Net profit margin
-687.61%
-710.81%
-735.19%
-416.15%
Earnings per share
-1.10
-0.98
-0.92
-0.83
Interest and investment income
8.60M
7.40M
6.71M
6.48M
Interest expense
-
-
-
-
Net interest expenses
8.60M
7.40M
6.71M
6.48M
Depreciation and amortization charges
-
-
-
-
EBITDA
-118.31M
-107.52M
-109.06M
-96.33M
Gain or loss from assets sale
-
-
-
527.00K
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer